|
Cerezo-Manchado JJ, Roldan V, Rosafalco M, Anton AI, Arroyo AB, Garcia-Barbera N, Martínez AB, Padilla J, Corral J, Vicente V, Gonzalez-Conejero R. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics. 2014 May;15(7):987-96. doi: 10.2217/pgs.13.232. PubMed PMID: 24956252.
AÑO: 2014; IF: 3.218
|
24956252
|
Gallego P, Roldán V, Marin F, Gálvez J, Valdés M, Vicente V, Lip GY. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014 Nov;127(11):1083-8. doi: 10.1016/j.amjmed.2014.05.023. PubMed PMID: 24858062.
AÑO: 2014; IF: 5.003
|
|
Roldán V, Arroyo AB, Salloum-Asfar S, Manzano-Fernández S, García-Barberá N, Marín F, Vicente V, González-Conejero R, Martínez C. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost. 2014 Oct;112(4):781-8. doi: 10.1160/TH14-01-0092. PubMed PMID: 25008481.
AÑO: 2014; IF: 4.984
|
|
Gallego P, Roldan V, Lip GY. Conventional and new oral anticoagulants in the treatment of chest disease and its complications. Am J Respir Crit Care Med. 2013 Aug 15;188(4):413-21. doi: 10.1164/rccm.201301-0141PP. PubMed PMID: 23672179.
AÑO: 2013; IF: 11.986
|
|
Jover E, Marín F, Roldán V, Montoro-García S, Valdés M, Lip GY. Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. Ann Med. 2013 May;45(3):274-90. doi: 10.3109/07853890.2012.732702. Review. PubMed PMID: 23216106.
AÑO: 2013; IF: 4.733
|